Expression of Vasohibin Family in Gastric Carcinoma.

Expression of Vasohibin Family in Gastric Carcinoma. - Expression of Vasohibin Family in Gastric Carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038219

Enrollment

210

Registered

2019-10-07

Start date

2017-07-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Gastric cancer patients who underwent radical surgery at Tokai University Hospital from January 2009 to December 2013.

Exclusion criteria

Exclusion criteria: Patients who were previously treated for cancers, residual, multiple, pT1a, or stage IV cancers, or multiple primary cancers with other tumors were excluded from our study.

Design outcomes

Primary

Measure	Time frame
The primary outcomes are to evaluate immunohistochemical expressions of Vasohibin-1 and Vasohibin-2 in gastric cancer and to investigate their clinicopathological significance.	—

Secondary

Measure	Time frame
The secondary outcomes are to examine the relationship between Vasohibin-1 and Vasohibin-2 immunohistochemical expression in gastric cancer, and to examine the relationship between the respective expression status and prognosis.	—

Countries

Japan

Contacts

Public ContactHara Hitoshi

Tokai University School of Medicine Department of Gastroenterological Surgery

h-hara@is.icc.u-tokai.ac.jp0463931121

Outcome results